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Clinical trials have indicated that autologous hematopoietic stem cell transplantation 
(HSCT) can persistently suppress inflammatory disease activity in a subset of patients with 
severe multiple sclerosis (MS), but the mechanism has remained unclear. To understand 
whether the beneficial effects on the course of disease are mediated by lympho-depletive 
effects alone or are sustained by a regeneration of the immune repertoire, we examined the 
long-term immune reconstitution in patients with MS who received HSCT. After numeric 
recovery of leukocytes, at 2-yr follow-up there was on average a doubling of the frequency 
of naive CD4
 
 
 
 T cells at the expense of memory T cells. Phenotypic and T cell receptor 
excision circle (TREC) analysis confirmed a recent thymic origin of the expanded naive T cell 
subset. Analysis of the T cell receptor repertoire showed the reconstitution of an overall 
broader clonal diversity and an extensive renewal of clonal specificities compared with 
pretherapy. These data are the first to demonstrate that long-term suppression of 
inflammatory activity in MS patients who received HSCT does not depend on persisting 
lymphopenia and is associated with profound qualitative immunological changes that 
demonstrate a de novo regeneration of the T cell compartment.
 
Multiple sclerosis (MS) is considered a T cell–
mediated inflammatory demyelinating disorder
of the central nervous system (CNS; reference
1), although other immune factors such as
complement and antibodies as well as factors
intrinsic to the CNS are thought to contribute
to disease expression. MS mainly affects young
adults and often leads to substantial disability at
an early age, resulting in enormous socioeco-
nomic costs. Most patients suffer from relapsing–
remitting disease, which later evolves into a
secondary chronic disease process. The role of
autoimmune inflammation is probably more
important during earlier stages of the disease,
when CNS damage is still limited. Once the
secondary progressive course has set in, in
some aspects MS resembles a neurodegenerative
disease with continuously increasing disability
and more limited or no inflammation. Cur-
rently, there is no curative treatment of MS,
particularly for patients with rapidly worsening
disease. Immunomodulatory agents have been
approved for relapsing–remitting MS but no
treatment, even intense immunosuppression,
appears to be effective during the later pro-
gressive disease stages. Phases I and II clinical
trials have suggested that immune ablation fol-
lowed by autologous hematopoietic stem cell
transplantation (HSCT) can suppress brain in-
flammation in the majority of high-risk patients
refractory to approved treatments and, in some,
may also arrest or delay progression of clinical
disability (2, 3).
The rationale for HSCT in autoimmune
diseases has been the notion that intensive im-
mune depletion could eliminate autoreactive
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immune cells irrespective of antigenic specificity and that re-
generating the immune system from hematopoietic precur-
sors could reestablish tolerance (4). However, available data
on immune reconstitution in patients with autoimmune dis-
ease are limited to 1 yr of follow-up posttransplantation at
most (5–8), and no study has demonstrated that HSCT can
actually “reset the immunological clock” by detecting phe-
notypic or functional renewal of the immune repertoire dur-
ing long-term clinical remission.
To address the question whether there is such immune
regeneration in patients with MS who cease to present in-
flammatory disease activity after the treatment, we studied
the mechanisms of long-term T cell reconstitution in seven
patients with MS that we prospectively followed for up to 3
yr after receiving a high-intensity myelo- and immunoabla-
tive HSCT regimen (Table I and Fig. 1). Our results estab-
lish that HSCT goes far beyond mere immune ablation and
provide evidence of extensive renewal of T cell repertoires
after HSCT.
 
RESULTS
Leukocyte recovery
 
First, we assessed basic aspects of the patients’ immune recon-
stitution by flow cytometry using leukocyte lineage and sub-
population markers. Because lymphocyte numbers are recon-
stituted early after HSCT (9), we expectedly found that mean
absolute lymphocyte counts (1.20 
 
 
 
 0.48 
 
 
 
 10
 
3
 
 cells/
 
 
 
L
blood) were already back to baseline levels at the 6-mo fol-
low-up (1.20 
 
 
 
 0.70 
 
 
 
 10
 
3
 
 cells/
 
 
 
L) and remained stable at
the 1-yr (mean 1.15 
 
 
 
 0.32 
 
 
 
 10
 
3
 
 cells/
 
 
 
L) and 2-yr follow-
ups (1.34 
 
 
 
 0.49 
 
 
 
 10
 
3
 
 cells/
 
 
 
L). At 6 mo and subsequent
time-points, there were no significant changes from prether-
apy in the proportions of CD3
 
 
 
 T cells, CD19
 
 
 
/CD20
 
 
 
 B
cells, NK (CD3
 
 
 
CD56
 
 
 
), NK T cells (CD3
 
 
 
CD56
 
 
 
), and
CD14
 
 
 
 monocytes (unpublished data). The CD4/CD8 ratios
were significantly decreased at 6 mo after HSCT compared
with baseline (mean 0.41 vs. 2.37; P 
 
 
 
 0.001) due to reduced
proportions of CD4
 
 
 
 T cells in the early posttransplant phase.
Consequent to the gradual normalization of CD4
 
 
 
 and
CD8
 
 
 
 T cell absolute counts, CD4/CD8 ratios were revert-
ing toward baseline levels at 1 yr (mean 0.73; P 
 
 
 
 0.002) and
were no longer significantly different at the 2-yr follow-up
(mean 1.79; P 
 
 
 
 NS), in agreement with data on immune re-
constitution in other diseases (10). The observed recovery of
lymphocyte numbers indicated that the prolonged absence of
new MS inflammatory disease activity after HSCT did not
require a persistent lymphopenia.
 
Increased naive T cells and decreased central–memory T cells 
after posttransplant immune reconstitution
 
Whether protective or pathogenic, T cell effector functions
are mediated by memory (peripherally primed) cells; there-
fore, elimination or reduction of memory cells is likely to
reduce the number of pathogenic cells in a subject with an
immune-mediated disorder. In contrast, the influx of de novo–
generated naive cells is recognized as an important compo-
nent of immune tolerance (11). To assess the effects of HSCT
on the size of the naive and memory T cell pools, we used
phenotypic markers that allow us to distinguish various func-
tional differentiation stages, including naive (T
 
naive
 
), central–
memory (T
 
CM
 
), and effector–memory (T
 
EM
 
) cells (12). The
longitudinal analysis of the frequency of these subpopulations
after HSCT is shown in Fig. 2. At 6 mo posttransplant, there
was a trend toward a reduction of naive (CD45RA
 
 
 
/
CD45RO
 
 
 
/CD27
 
 
 
) CD4
 
 
 
 T cells (CD4 T
 
naive
 
), consistent
with the prevalence of effector–memory phenotypes resulting
from homeostatic proliferation in a lymphopenic environ-
ment (13–15). Central–memory (CD45RA
 
 
 
/CD45RO
 
 
 
/
CD27
 
 
 
) CD4
 
 
 
 cells (CD4 T
 
CM
 
) decreased steadily during
the posttransplant follow-up. The proportion of effector–
Figure 1. Resolution of inflammatory disease activity after HSCT. 
Representative contrast-enhanced MRI axial scans of the brain of patient 
2 at pretransplant evaluation (top) and at 2-yr follow-up (bottom) illus-
trate a long-lasting resolution of inflammatory disease in this patient with 
high pretransplant activity (arrows point at 3 out of 17 total enhancing 
lesions present in the brain pretherapy; no enhancing lesions were de-
tected after therapy).
 
Table I.
 
Demographic and clinical features of patients
 
Patient
code Gender/age
Disease
course
 
a
 
Clinical
relapses
in 2 yr
before HSCT
Clinical
relapses
after HSCT
Clinical
follow-up
after HSCT
 
yr no. mo
 
1 M/53 SP-MS 2 0 36
2 M/30 RR-MS 4 0 28
3 F/53 SP-MS 3 0 28
4 M/28 PR-MS 2 0 28
5 M/45 PR-MS 4 0 27
6 F/47 SP-MS 2 0 25
7 M/51 SP-MS 2 0 21
 
a
 
PR-MS, progressive–relapsing MS; RR-MS, relapsing–remitting MS; SP-MS, 
secondary progressive MS.  
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memory (CD4
 
 
 
/CD45RA
 
 
 
/CD45RO
 
 
 
/CD27
 
 
 
) CD4
 
 
 
cells (CD4 T
 
EM
 
) rose significantly at 6 mo after HSCT and
later declined toward baseline levels after the gradual replen-
ishment of the absolute CD4
 
 
 
 T cell numbers. Of note,
when we examined the net outcome at the end of the 2-yr
follow-up, we found a more-than-doubled frequency of
CD4 T
 
naive
 
 as compared with pretherapy (118% increase; P 
 
 
 
0.032). Correspondingly, CD4 T
 
CM
 
 cells were significantly
decreased at 2 yr after therapy (by 38%; P 
 
 
 
 0.008). The fre-
quencies of CD4 or CD8 T
 
EM
 
 and of CD8 T
 
naive
 
 did not
change significantly at the 2-yr follow-up compared with the
baseline. The atypical effector–memory phenotype of oligo-
clonally expanded CD8
 
 
 
 cells appearing posttransplant, as
shown later, should be taken into account for the interpreta-
tion of these data. There was a trend to a decrease of CD8
T
 
CM
 
 percentages at the 2-yr follow-up (32% reduction), but
the study was underpowered to assess the statistical signifi-
cance. Together, our analysis showed that approximately one
fourth of the CD4
 
 
 
 cell pool occupied by CD4 T
 
CM
 
 was re-
populated by CD4 T
 
naive
 
 cells, leading to a 76% reduction of
CD4 T
 
CM
 
/CD4 T
 
naive
 
 ratios (from 4.72 to 1.12; P 
 
 
 
 0.035).
These data support the notion that HSCT can induce a phe-
notypic rejuvenation of the CD4
 
 
 
 T cell repertoire.
 
Increased output of recent thymic emigrants (RTEs)
 
To determine the source of the increase of phenotypically
naive CD4
 
 
 
 cells, we took two approaches to assess the thy-
mic versus peripheral origin of the reconstituted T cell pool.
To identify RTEs in the CD4
 
 
 
 subset, we first used as
marker the expression of CD31 in combination with
CD45RA and CD45RO, as described recently (16). The
mean frequency of CD4 RTEs (CD4
 
 
 
/CD45RA
 
 
 
/
CD45RO
 
 
 
/CD31
 
 
 
), reduced at 6 mo posttransplant, subse-
quently recovered and doubled from 18% at baseline to 36%
at 2 yr after HSCT (P 
 
 
 
 0.028; Fig. 3 A). To confirm and
extend the analysis, we used a highly specific assay to mea-
sure the presence of de novo–generated T cells in peripheral
blood based on the quantification of T cell receptor excision
circles (TRECs). TRECs are stable DNA episomes formed
during rearrangement of the TCRAD locus during T cell
Figure 2. Phenotypic analysis of naive and memory T cell popula-
tions. All values are the percent expression of the indicated T cell subpop-
ulation at pretherapy and follow-up time points. (left) Subsets of CD4  T 
cells and (right) subsets of CD8  T cells, each categorized as Tnaive, naive T 
cells; TCM, central–memory T cells; and TEM, effector–memory T cells. The 
boundaries of the boxes indicate the 25th and 75th percentiles, the lines 
within the boxes indicate the median, and the whiskers mark the 10th and 
the 90th percentiles. We observed a statistically significant (greater than 
twofold) increase of CD4 Tnaive and a decrease of CD4 TCM.
Figure 3. Measures of thymic output after HSCT. (A) Phenotypic 
identification of RTEs in the CD4  subset showed a significant increase of 
CD4  RTEs at 2-yr follow-up. (B) TCR excision circle (TREC) analysis showed 
full reconstitution and increases of CD4 RTE output at 2-yr follow-up. 
(C) Due to extensive peripheral cell division, CD8 TREC levels only recovered 
up to near-pretherapy levels. Age–related interindividual variance and the 
small number of patients precluded a statistical evaluation of TREC data. 
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differentiation in the thymus. Because TRECs do not repli-
cate with cell division, they have been successfully used as a
marker for RTEs (17). We followed the evolution of TREC
levels after HSCT in purified CD4
 
 
 
 and CD8
 
 
 
 T cells (Fig.
3 B). As expected, TREC content was generally decreased
in both subsets early (6 mo) posttransplantation, when im-
mune reconstitution predominantly relies on peripheral ex-
pansion of the autologous graft. However, starting 1 yr after
HSCT, CD4 TREC levels rebounded from a median of 848
TRECs/10
 
5
 
 CD4
 
 
 
 cells at baseline to 6,689 TRECs/10
 
5
 
CD4
 
 
 
 cells at 1 yr and 4,602 TRECs/10
 
5
 
 CD4  cells at the
2-yr follow-up (a 7.9-fold and 5.4-fold increase, respec-
tively). Due to the small number of patients and interindi-
vidual variance (largely age-related), our study was under-
powered to assess the statistical significance of this increase.
Most patients recovered pretransplant CD8 TREC at the
1-yr follow-up and after, but there was no overall increase at
the end of the 2-yr observation period (Fig. 3 C). When we
examined the correlation of the frequency of phenotypically
identified CD4  naive cells and CD4 RTEs, we found no
correlation in the early (6 mo) posttherapy phase, but a
strong correlation was reestablished at 1 yr (Pearson’s r  
0.982 with P   0.002) and further increased its significance
at the 2-yr follow-up; r   0.988 with P   0.001). This ob-
servation established further evidence to suggest a true thy-
mic origin for the observed phenotypic rejuvenation of the
CD4  T cell repertoire.
Recovery of T cell receptor repertoire diversity
First, we followed the reconstitution of the peripheral blood
TCR V  repertoire using a panel of TCR V –specific
monoclonal antibodies and flow cytometry at baseline and at
the 6-mo, 1-yr, and 2-yr follow-ups. One patient showed a
transient TCR V  expansion in the CD4  T cell subset
(patient no. 1, V 17 at 6 mo after HSCT). In the remaining
patients (e.g., patient no. 4; Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20041679/DC1), the
TCR V  profiles of CD4  T cells remained stable through-
out the follow-up. In contrast, we frequently detected expan-
sions of individual TCR V s after HSCT in the CD8  subset
(Table II). These expansions were not associated with clinical
or laboratory signs of infection or with MS relapses. After a
2-yr follow-up, reconstituted TCR V  repertoires of CD4 
T cells were very similar to the pretransplant repertoires,
showing in each patient  4% absolute difference of expres-
sion for each TCR V . Due to the persistent expansion of
CD8  T cells expressing individual V s, we detected larger
differences in the 2-yr posttherapy profiles of TCR V  ex-
pression for the CD8  subset. Multidimensional scaling anal-
ysis illustrated how closely the reconstituted TCR V  reper-
toires resembled each individual’s pretreatment profile for
CD4  cells (Fig. S2, available at http://www.jem.org/cgi/
content/full/jem.20041679/DC1). This trend was seen to be
more limited when looking at CD8  cells.
To investigate in greater depth the evolution of the pe-
ripheral TCR repertoire after HSCT, we used TCRB CDR3
spectratyping. This technique allows us to assess the clonal
composition of a T cell population and its overall diversity
based on the length of TCRB CDR3 (18, 19). For CD4 
cells (12 samples analyzed), in every instance a full CDR3
length diversity was restored at 2 yr of follow-up, both when
CDR3 distribution at baseline was skewed (Fig. 4 A and not
depicted) and when it was normally diverse (Fig. 4 B and not
depicted). In the CD8  subset (72 samples), TCRBV expan-
sions appearing at 6 mo or 1 yr after HCST were usually asso-
ciated with a skewed, oligo-, or monoclonal CDR3-length
distribution (Fig. 4, A and C, and not depicted). Some CDR3
peaks that were dominant at baseline reemerged at follow-up,
indicating that oligoclonal T cells that had rearranged the
same TCRBV gene and a CDR3 of equal length either per-
sisted or were selected and expanded again after HSCT (Fig. 4
C). In six out of seven patients, both for the CD4 and for
CD8 subsets, we observed almost exclusively the first two
patterns presented in Fig. 4 (i.e., increased or preserved diver-
sity). In patient 5, we frequently observed the reappearance
posttherapy of CD8  T cells with the same CDR3 length.
Interestingly, this was the only patient who had recurrent in-
fectious events during follow-up and the only patient who
had a substantial loss of CD8 TREC posttherapy. However,
even when we found a skewed CDR3-length distribution
posttherapy, the CDR3 peaks that were dominant pretherapy
became subdominant posttransplant, outnumbered by others
that were underrepresented or undetectable before therapy
(Fig. 4 C and not depicted). Overall, normal CDR3 length
distribution was reconstituted for the majority of the TCR
repertoires, suggesting increased clonal diversity from de novo
TCR rearrangement.
Extensive clonal T cell renewal after HSCT
To examine a section of the TCR repertoire at the single
clone level, we cloned and sequenced TCRB transcripts
from sorted peripheral blood CD4  and CD8  T cells ob-
Table II. Significantly expanded TCR V –expressing cells 
after HSCT
Patient T subset TCR Pre-Txa
6 mo
after Tx
1 yr
after Tx
2 yr
after Tx
1 CD4  BV1 2.5 8.8b ND 3.5
CD4  BV17 10.5 32.0 ND 9.3
2 CD8  BV18 0.5 6.1 2.2 2.0
CD8  BV20 2.6 7.6 8.1 9.4
4 CD8  BV1 5.7 4.2 15.6 9.8
5 CD8  BV8 6.9 17.9 14.0 18.9
CD8  BV21.3 1.4 3.6 2.9 6.6
6 CD8  BV1 5.2 ND 17.5 9.9
CD8  BV5.1 3.5 ND 8.6 9.4
7 CD8  BV5.1 1.75 6.8 4.7 ND
CD8  BV23 0.3 49.9 53.9 ND
aTx, treatment.
bBold numbers indicate a significant expansion according to the criteria described in 
Materials and methods.JEM VOL. 201, March 7, 2005 809
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tained at baseline and posttreatment. We selected 10 sample
pairs (preTx and corresponding 1-yr or 2-yr follow-up) cov-
ering the three different patterns of reconstitution of TCR
repertoire diversity observed by CDR3-length spectratyping
and sequenced 90 clones on both DNA strands for each sam-
ple (patient/time point/T subset/BV gene). Representative
results of sequencing-based clonotypic analysis for each of
the three categories are shown in Fig. 5. When CDR3-
length diversity was increased or maintained (spectratyping
patterns A and B, respectively), we observed a very substan-
tial or complete renewal of the clonal specificities. New se-
quences represented from 90 to 100% of the examined por-
tion of T cell repertoire (Fig. 5, A and B, and not depicted).
For sample pairs with spectratyping pattern A, the vast ma-
jority of the new sequences in the posttherapy T repertoire
fraction examined were unique clones (appearing only
once), consistent with the notion of increased repertoire di-
versity (Fig. 5 A and not depicted). Surprisingly, the propor-
tion of unique sequences increased posttherapy also for sam-
ple pairs that had a spectratyping pattern B (Fig. 5 B and not
depicted), demonstrating an increased diversity of individual
clones within each CDR3 length (i.e., within each spec-
tratyping peak). In the fewer observed instances of limited
CDR3-length diversity posttherapy (pattern C), the propor-
tion of unique sequences was reduced, as expected. The fre-
quency of expanded clones (same TCR sequence appearing
more than once) was always decreased posttherapy in pat-
terns A and B (Fig. 5, A and B, and not depicted). In con-
trast, for pattern C, the total frequency of expanded clones
was increased posttherapy. However, the hierarchy of fre-
quency of preexisting individual clones was often reversed
posttherapy (i.e., dominant clones became subdominant and
vice versa). In addition, to our surprise, newly appearing
clones (both expanded and not expanded) represented up to
100% of all TCRBV gene family transcripts in posttreatment
samples with limited clonal diversity, indicating that clonally
expanded populations could originate to a large extent or
even entirely from de novo–selected T cells (Fig. 5 C and
not depicted). The extent of clonal renewal, defined as the
percentage of new sequences posttherapy (including both
nonexpanded and expanded clones) ranged from 89.4 to
100% for group A, from 90.4 to 100% for group B, and from
12 to 100% for group C.
Effects on peripheral aspects of immune reconstitution
Because peripheral mechanisms of immune homeostasis dur-
ing and after immune reconstitution may also contribute to
the remission of inflammatory disease activity, we examined
by flow cytometry immunological markers of cell activation,
costimulation, adhesion, chemotaxis, and apoptotic pathways
on T cells, B cells, monocytes, and T cell subsets. Among the
most significant changes we observed a prominent increase in
the frequency of CD95/Fas  T cells at 6 mo posttransplant
(P   0.002 for the CD8  subset), suggesting an increased
susceptibility to Fas/FasL-mediated apoptosis (Fig. 6 A). We
focused further analyses on the CD8  subset because previ-
ous papers (9, 10) and our emerging data suggested a major
contribution of CD8  T cells to the peripheral (postthymic)
component of immune reconstitution. After HSCT, a larger
proportion of CD8  cells lacked CD28 expression and ex-
pressed CD57 (P   0.001 at all time-points posttherapy com-
pared with baseline; Fig. 6 B). CD8 /CD28 /CD57  T
cells have been described recently as a subpopulation that is
unable to expand upon stimulation and is highly susceptible
to apoptosis (20). Considering the aforementioned oligo-
clonal T cell expansions in the CD8  subset after HSCT, we
Figure 4. Analysis of TCR diversity. High-resolution TCRBV CDR3 
spectratyping analysis identified three basic patterns of evolution of rep-
ertoire diversity: (A) recovery of diversity from a restricted repertoire, (B) 
reconstitution of diversity from a normally diverse repertoire; (C) and total 
or partial persistence (or reemergence) of repertoire skewing. Different 
numbers of examples are shown to convey a correct impression of the 
observed frequency of each pattern. Patterns A and B were largely pre-
dominant except for patient 5, who had recurrent infections. Vertical lines 
are reference DNA size markers to provide the exact correspondence of 
CDR3 peaks across different samples. n.d., not determined (due to unavail-
ability of 2-yr follow-up for patient 7).T CELL REGENERATION AFTER HSCT IN MS | Muraro et al. 810
investigated the nature of these expansions with relevant cell
surface markers, alone or in combination with specific TCR
V  staining (Fig. 7, A and B). The examination of oligo-
clonal T cell expansions based on back-gating on the ex-
pressed TCR V  (Fig. 7 B) showed that  95% of the ex-
panded TCR V –bearing cells was CD57  (Fig. 7 C).
Further characterization described these cells as CD95/Fas ,
CD45RA /CD45RO /CD27  atypical effector–memory
CD8  T cells (Fig. 7 C). Because CD8 /CD57 /CD28  T
cells represent a state of proliferative senescence reached after
extensive division in vivo and loss of TRECs (20), their ex-
pansion after HSCT accounted for the lack of increase (or
Figure 5. Extensive clonotypic renewal within the T cell repertoire. 
We cloned and sequenced 90 clonal TCRs from sample pairs for each of 
the three patterns of evolution of CDR3 length diversity previously identi-
fied by spectratyping. One representative example is shown for each pattern. 
Colored pie slices represent individual expanded T clones. Color and size of 
slices allow identification of the expanded clones and show their relative 
frequency, respectively. The group of nonexpanded clones (unique sequences, 
not shown individually for their large numbers) is shown in light gray in 
pretransplant samples and in white in posttransplant samples and, within 
each one, the proportion of single clones persisting posttransplantation is 
shown in dark gray. For the predominant patterns in A and B, we found a 
prominent increase of unique sequences, denoting increased clonal diver-
sity also within the same CDR3 length. Pre-existing expanded clones were 
either undetectable or reduced after therapy. In the less frequent pattern 
in C, preexisting or new expanded clones constituted the majority of the 
examined T repertoire after therapy.JEM VOL. 201, March 7, 2005 811
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loss) of CD8 TRECs posttherapy in the individuals with
more prominent or persistent TCR V  expansions in the
CD8  subset (patient nos. 2, 5, and 7).
DISCUSSION
MS is an inflammatory disease believed to have a T cell–
mediated autoimmune origin. To understand the capacity of
T cells to regenerate after autologous HSCT in patients with
MS, we focused on the long-term posttherapy reconstitution
of the T cell immune compartment. The main question we
wanted to address was whether the favorable effects of
HSCT on the inflammatory component of disease are
related to a “resetting” of the adaptive immune system, as
often postulated, or are simply the result of a long-lasting
lymphocyte depletion induced by the high-dose immunoab-
lative therapy. Because, in our work, the recovery of leuko-
cyte and T cell subset absolute numbers was not associated
with reemergence of inflammatory disease activity, other
changes in the immune systems must be considered to ex-
plain the observed disease relapse-free interval for the entire
2-yr posttherapy follow-up.
Our data show that a thymopoietic pathway of T cell
regeneration is activated in MS patients treated with HSCT
and leads to immune renewal. The evidence supporting this
notion is as follows: (a) the increased frequency of pheno-
typically naive CD4  T cells; (b) the decreased frequency of
central–memory T cells; (c) the expansion of phenotypically
identified CD4  RTEs; (d) the increased TREC levels
in the CD4  subset and the adequate recovery of CD8
TRECs in spite of extensive peripheral division in this sub-
set; (e) the overall improved clonal diversity of the TCR
repertoire; and (f) the extensive clonotypic renewal shown
Figure 6. Phenotypic changes of the peripheral T cell repertoire. 
(A) Transient increase of CD95/Fas  in the CD4  and CD8  T cell subset 
in the early (peripheral) phases of immune reconstitution, suggesting an 
increased susceptibility to Fas/FasL-mediated apoptosis. Representative 
histograms from an individual patient are shown (left) as is a summary of 
data from all patients (right). (B) Persistent increase of CD8 /CD28 /CD57  
T cells during follow-up. (left) An individual patient’s example of CD8  
gated analysis with the top histograms showing CD57 expression, and dot 
plots (bottom) showing CD57 (x axis) versus CD28 (y axis) expression. 
(right) The box plot summarizes the data from all patients. CD8 /CD28 /
CD57  have been characterized as a terminally differentiated subpopula-
tion with short telomeres, defective cytolytic functions, and increased 
susceptibility to apoptosis.T CELL REGENERATION AFTER HSCT IN MS | Muraro et al. 812
by comparison of pre- and posttherapy TCRBV transcripts.
Thymus-dependent T cell regeneration is more vigorous in
the early childhood (21), but recent data have shown that
the thymus is still active through adult life (22). However,
patients with MS have age-inappropriate TREC levels, sug-
gesting an intrinsic impairment of thymic export (23). A
major finding of our study is the simultaneous reemergence
posttherapy of phenotypically naive CD4  cells and CD4 
RTEs, which led to a doubling of their frequency at 2 yr
posttransplantation compared with pretherapy. This obser-
vation suggests that increased thymopoiesis (“thymic re-
bound”) after HSCT can correct the preexisting deficiency
and normalize naive T cell homeostasis. Recent studies in
animal models have shown that reconstitution of the thy-
mus by hematopoietic stem cells, rather than peripheral ho-
meostasis, determines peripheral naive CD4  T cell recon-
stitution (24). Irradiation of the host was required for
accumulation of naive T cells (24, 25). Whether total body
irradiation (TBI), used in our treatment regimen, is also a
requirement in humans for the induction of naive cell ex-
pansion remains to be determined. The reciprocal decrease
of central–memory T cells we observed is intriguing in the
context of MS because this subset represents the major
component of cerebrospinal fluid T cells (12), and memory
cells are more easily triggered and more cross-reactive than
naive cells. The overall increased diversity of TCRB
CDR3-length repertoire is also consistent with increased
thymic output (11). The aforementioned observations con-
trast with available data from conventional chemotherapy
for MS, including pulse cyclophosphamide and mitoxan-
trone, which both lead to decreased CD4  total and naive
cell numbers, arguing for immunosuppressive effects rather
than for immune renewal (26, 27).
Using a sequencing-based clonotypic analysis, we ex-
plored for the first time at the single clone level the reconsti-
tution of TCR repertoire after HSCT in an immune-medi-
ated disease. Two important observations emerged from our
data; first, the extent of T cell repertoire renewal is even
greater ( 90% in most cases) than what could be anticipated
from the increase of naive cells and of RTEs or from the re-
constitution of CDR3 length diversity that we have ob-
served. Second, although the renewal of clonal specificities is
extensive, it is not always complete, and some preexisting in-
dividual T cell clones, more frequently in the CD8  subset,
can be found again in the peripheral blood after HSCT. To
understand the origin of the persisting clones, we are at-
tempting to track them in the minor T cell component con-
taminating the CD34  enriched hematopoietic stem cell
graft. The relevance for disease of these clones remains un-
clear. In fact, their persistence in subjects showing a sustained
remission of inflammatory disease activity suggests that either
these clones were not self-reactive pathogenic mediators or
they are not able to induce disease activity under the new
conditions produced by the immune reconstitution.
Early thymus-independent pathways dictate a faster nu-
meric regeneration of CD8  T cells than for CD4  cells,
and the observation of clonal expansions in the CD8  subset
suggests a role of antigen-specific differentiated cells in its
repopulation. Our data show that oligoclonal cells are a ma-
jor constituent of the expansion of CD8 /CD28 /CD57 
T cells. Because of their ambiguous phenotype and the co-
expression of high and low molecular weight CD45R iso-
forms, these cells cannot be reliably classified as central– or
effector–memory cells according to conventional schemes.
Extensive peripheral cell division in the CD8  subset re-
duces TREC content and probably masks an underlying in-
crease from thymic rebound, leading to an underestimate of
the frequency of naive CD8  and CD8 RTEs as suggested
previously (11). The activation of similar cell populations in
recipients of HSCT has been correlated to previous expo-
Figure 7. Characterization of oligoclonally expanded CD8  popu-
lations. (A) In the example shown, TCR V  back-gating in combination 
with CDR3 spectratyping of CD8  T cells (top inlays: black box, preHSCT; 
red box, 6-mo follow-up) demonstrates that oligoclonal expanded cells, 
representing up to 50% of all CD8  cells (B), are CD57 /CD45RA /
CD45RO /CD27 /CD95(Fas)  (C), consistent with the phenotype of atypical 
effector–memory cells that reached replicative senescence after extensive 
division in vivo.JEM VOL. 201, March 7, 2005 813
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sure to CMV (9, 28), leading to the notion that CD28 /
CD57  cells are differentiated memory CD8  populations
expanded in the presence of persistent viral antigens. CD8 /
CD28 /CD57  T cells have limited TCR diversity also in
healthy subjects (29, 30), have short telomeres (20, 31), are
unable to proliferate in vitro, and are highly susceptible to
apoptosis (20). Consistent with the latter observation, the el-
evated frequency of Fas CD8  (and CD4 ) cells that we
and others found in the early phases of immune reconstitu-
tion has been linked to a generally increased propensity to
apoptosis (32, 33). Based on all these characteristics, the
CD8 /CD28/CD57  phenotype has been viewed as a sig-
nature of “clonal exhaustion” or “replicative senescence”
(20, 34, 35). The expansion of atypical, terminally differ-
entiated CD8  cells may be implied in the control of
autoimmunity by restricting the space available in the effec-
tor–memory niche for other cells, possibly including autore-
active effectors, through a process known as attrition (13,
36). In addition, CD8 /CD28 /CD57  T cells can exert an
immunoregulatory role mediated via an unidentified soluble
factor (37–39).
Further studies are required to better understand the
mechanisms that underlie these observations and their possi-
ble implications for immune tolerance. Here, we showed
that a sequential combination of thymus-independent pe-
ripheral reconstitution pathways (early; CD8   CD4) and
thymus-dependent immune rejuvenation (later; CD4  
CD8) profoundly reconfigures the immune system in pa-
tients with MS who received HSCT and results in a pro-
longed disease activity-free interval that is not reliant on im-
munosuppression. These findings substantiate the induction
of immune regeneration as the rationale of HSCT and pro-
vide a mechanistic basis for ongoing and future clinical trials
of this therapeutic strategy in autoimmune diseases.
MATERIALS AND METHODS
Clinical trial protocol.  Enrollment in the protocol required a diagnosis
of clinically definite MS (40) and a neurological progression during the year
before screening evaluation of at least 1.5 steps on the expanded disability
status scale (EDSS; a measure of disability ranging from 0 for a normal neu-
rologic exam to 10 for death as a result of MS; reference 41) if their initial
grade was 6.0 or less, or at least 1.0 step if their EDSS at screening was
 6.5. Additional inclusion criteria required that baseline EDSS levels had to
be sustained for at least 3 mo and unresponsive to high dose steroid treat-
ment. The study was approved by the U.S. Food and Drug Administration
under IDE 6440 and by the institutional review boards of Northwestern
University and of the National Institute of Neurological Disorders and
Stroke, National Institutes of Health. Seven patients with MS (Table I) gave
informed consent and were consecutively enrolled in the study. Peripheral
blood stem cells were collected by leukoapheresis after infusion of 2.0 g/m2
cyclophosphamide followed by daily G-CSF (5  g/kg/d) beginning 72 h
after cyclophosphamide infusion. The graft was enriched for CD34  cells
by Isolex (Baxter) stem cell concentrator. Data on the purity of the CD34 
enriched hematopoietic stem cell grafts are reported in Table III. Immune
ablation was achieved by 60 mg/kg/d cyclophosphamide intravenously for
2 d, followed by TBI in doses of 150 cGy, twice daily, for a consecutive 4 d
(total dosage of 1,200 cGy). 1 g methylprednisolone was administered intra-
venously on each of the 4 d of TBI. Further details of the clinical trial have
been published (42).
Clinical responses to HSCT. All seven patients successfully completed
the protocol treatment. There were no transplant-related toxicities during
follow-up. Patient 5 had recurrent episodes of Clostridium difficile enterocoli-
tis after HSCT. No infectious events were observed in the other six patients
during follow-up. All patients remained free of clinical MS relapses after
HSCT for a mean follow-up of 27.6 mo (range: 21–36 mo) without receiv-
ing any immunosuppressive or -modulatory treatment (Table I). Magnetic
resonance imaging (MRI) of the brain (and of the spinal cord for four pa-
tients) performed at 6 mo after HSCT and yearly thereafter showed an ab-
sence of gadolinium-enhancing lesions for a mean follow-up of 30 mo
(range: 24–36 mo) as exemplified in Fig. 1. Clinical disability at 2-yr fol-
low-up improved in one patient (from EDSS 3.5 to 1.0) and remained sta-
ble (variation of EDSS   0.5) in five patients. One patient (no. 7) who had
progressively worsened by 1.0 EDSS point at 1 yr after HSCT was lost to
follow-up because of accidental injuries at 21 mo after HSCT. During the
Table III. Purity of the CD34  enriched hematopoietic stem cell grafts
Patient Graft no.a Volume
Percent
CD34 /ml
No. of
CD34 /ml
Total
CD34  infusedb Percent CD3 
No. of
CD3 /ml
Total
CD3  infusedb
ml
1
1 101 92.0 2.21   106
4.07   108 0.10 2.40   103
8.54   105
2 102 90.4 1.81   106 0.30 6.00   103
2 1 102 96.3 5.49   106 5.60   108 0.20 1.14   104 1.16   106
3 1 102 93.5 4.39   106 4.48   108 0.10 4.70   103 4.79   105
4 1 103 71.8 4.88   106 5.03   108 0.10 6.80   103 7.00   105
5 1 101 92.7 3.24   106 3.28   108 0.10 3.50   103 3.53   105
6 1 103 70.4 1.83   106 1.89   108 0.60 1.56   104 1.61   106
7
1 102 63.3 1.20   106
2.81   108 0.60 1.14   104
1.37   106
2 102 77.7 1.55   106 0.10 2.00   103
Average 102 83.1 2.96   106 3.88   108 0.24 7.09   103 9.32   105
aFor patients 1 and 7, the number of mobilized CD34  obtained from the first leukapheresis was insufficient; therefore, a second collection was performed the following day.
bFor patients 1 and 7, we indicate the total combined number of CD34  and CD3  cells calculated from graft nos. 1 and 2 that were infused into the patient. The purity of each 
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available posttherapy follow-up, this patient had no clinical relapses or MRI
evidence of disease activity. Therefore, chronic progression of disability was
probably consequent to axonal degenerative processes that may occur in
progressive stages of disease even in the absence of inflammation (42–44).
For the purposes of this study, the absence of exacerbations and absence of
active or new lesions posttherapy after HSCT in all patients indicated a pro-
found effect on the inflammatory component of MS pathogenesis, consis-
tent with other reports (45–47).
Cells and immunophenotypic analyses.  Routine complete blood
counts and differential white blood cell counts were obtained at study visits.
PBMCs were collected at baseline before stem cell mobilization and at 6, 12,
and 24 mo posttransplant and were isolated and cryopreserved according to
standard methods. We examined the expression of a large panel of cell surface
markers on T cells, B cells, monocytes, and T cell subsets using four-color
FACS analysis. The markers included molecules crucially involved in T cell
activation, costimulation, chemotaxis, apoptosis, adhesion, and transmigration
as well as markers of specialized T cell subpopulations. A total of 24 different
mAb combinations allowed the acquisition and analysis of a minimum of 98
immunological measures for each PBMC sample. The following antibodies
were purchased from BD Biosciences: CD3 Cy-Chrome, CD8 FITC, CD8
PE, CD14 allophycocyanin, CD14 FITC, CD14 PE, CD31 PE, CD19 FITC,
CD28 PE, CD40 FITC, CD40 Cy-Chrome, CD45RA FITC, CD45RO PE,
CD45RO allophycocyanin, CD49d FITC, CD54 (ICAM-1) PE, CD56
PE, CD58 (LFA-3) FITC, CD69 FITC, CD74 FITC, CCR4 PE, CCR5 PE,
CXCR3 PE, CXCR4 PE (BD), CD134 (OX-40) FITC, CD134 (OX-40)
FITC, CD152 (CTLA-4) PE, CD154 (CD40L) PE, CD80 PE, CD86 FITC,
CD95 PE, HLA-DQ FITC, HLA-DR FITC, HLA-DR Cy-Chrome, TCR
    FITC, TCR     PE, IgG1 Cy-Chrome, IgG2a   PE, IgG2a   FITC,
IgG2b   FITC, and IgG2b   PE. We purchased the following antibodies from
Exalpha: CD4 FITC, CD4 RPE-Cy5, CD8 allophycocyanin, CD19 FITC,
CD25 FITC, CD27 FITC, CD45RA PE, CD69 FITC, CD117 (C-KIT L)
FITC, IgG1 FITC, IgG1 PE, IgG1 RPE-Cy5, IgG1 allophycocyanin, and
IgG2a   allophycocyanin. The antibodies CD45RO FITC and CD83 PE
were obtained from Beckman Coulter. CCR1 PE, CCR2 PE, CCR3 FITC,
and CCR5 FITC were obtained from R&D Systems.
Stringent control of antibody lot consistency, staining conditions, and
instrument setup allowed excellent interexperimental reproducibility (un-
published data).
Measurement of thymic output.  Frequency of RTEs in peripheral
blood was evaluated by quantitative PCR for detection of TRECs as de-
scribed previously (22). In brief, we purified CD4  and CD8  T cell sub-
sets using MACS microbeads (Miltenyi Biotec). Sorted cells ( 95% pure by
FACS analysis) were counted and lysed with proteinase K, and the exposed
DNA was used directly as template for real-time quantitative PCR amplifi-
cation and quantification. Real-time PCR was run in duplicate tubes, and a
standard curve was generated from a plasmid TREC DNA serial dilution
(six concentrations), allowing absolute TREC quantification and accurate
measuring of TREC per unit number of cells.
Analysis of TCR repertoire. We performed an analysis of TCR V  ex-
pression on peripheral blood CD4  and CD8  T cells by four-color FACS
analysis using 22 TCR V –specific monoclonal antibodies as described pre-
viously (48). TCR designations are according to Arden’s nomenclature
(49). A TCR V  was defined significantly expanded at follow-up when its
percent expression met all three of the following criteria: (a) exceeding by at
least 2 SD the mean expression in a reference population of 64 healthy do-
nors (48); (b) being at least twice the baseline expression in that individual;
and (c) being  5% of all TCR V   cells.
To analyze the clonal heterogeneity of TCRBV gene rearrangements
by CDR3 spectratyping, CD4  and/or CD8  T cell subsets were positively
selected using MACS (Miltenyi Biotec). Purity of sorted subsets was  95%.
RNA was isolated using TRIzol (Invitrogen) and complementary DNA
(cDNA) was synthesized using SuperScript II and Oligo-dT (both obtained
from Invitrogen) according to the manufacturer’s instructions. TCRB rear-
rangements were amplified from cDNA using BV family–specific oligonu-
cleotide primers essentially as described previously (48) and 2.5  l of PCR
amplification product from each TCR BV were used as template in a 12.5
 l primer-extension (“runoff”) reaction containing 1.25  l of 5  FAM-
labeled BV primer, 0.25  l of 10 mM dNTP (Invitrogen), 0.06  l PFU
DNA polymerase (Promega), 1.25  l PFU reaction buffer, and 7.2  l H2O.
After thermal cycling (95 C for 2 min; followed by 10 cycles of 94 C for
20 s, 55 C for 45 s, and 72 C for 45 s, and a final extension of 72 C for 10
min), 2  l of runoff reaction product was mixed with a loading buffer con-
taining four Cy-5–labeled DNA-size markers (sizes 103, 152, 205, and 261
bp), heat treated at 80 C for 2 min, and run on a 6% polyacrylamide gel on
an OpenGene (Visible Genetics) sequencer. Electropherograms were ana-
lyzed using the OpenGene software package. Analysis included peak size
(expressed in base pairs), peak height, and area under the curve (AUC). For
evaluation of normal (Gaussian) versus skewed (oligoclonal) CDR3-length
distribution, the percentage represented by each CDR3 peak in a BV spec-
trum (corresponding to the representation of clonal populations with a
given CDR3 length) was calculated according to the formula %AUC BVn  
(AUC BVn /  AUC all BV)   100.
For TCR  -chain sequencing, TCRBV rearrangements were amplified
from CD4  or CD8  sorted cells essentially as described before, and ampli-
cons were purified by agarose gel electrophoresis using the Gel Extraction
Kit (QIAGEN). The purified DNA fragments were ligated into a pGEM-T
Easy vector (Promega) and were used to transform DH5  Escherichia coli (In-
vitrogen) competent cells. For each TCRBV 90, individual bacterial colo-
nies were selected by blue/white screening, and plasmid DNA was extracted
using standard methods. Samples were sequenced on an ABI 373 automated
sequencing system. Dye-labeled vector-specific primers (T7-forward and
Sp6-reverse) were used to sequence both strands of each clone. Sequence
analysis was completed with the Genetics Computer Group–Lite Software,
and TCR rearrangements were analyzed using IMGT, the international Im-
MunoGeneTics information system at http://imgt.cines.fr.
Statistical analysis.  The statistical significance of immunological changes
was longitudinally evaluated by one-way repeated measures analysis of vari-
ance (RM-ANOVA). When RM-ANOVA identified a statistically signifi-
cant change, the Tukey post-hoc test was applied. When appropriate, the
paired Student’s t test or the nonparametric Mann-Whitney rank sum test
was applied. To test for correlation of normally distributed variables, we
used Pearson’s correlation coefficient.
Online supplemental material. Fig. S1 exemplifies an analysis of TCR
V  expression for the CD4 and the CD8 subsets during a 2-yr follow-up
and the detection of a significant T cell expansion in the CD8 subset. Fig.
S2 depicts a multidimensional scaling analysis of the extent of similarity of
the reconstituting TCR V  profiles for the CD4 and CD8 T cell subsets of
each patient. Online supplemental material is available at http://www.
jem.org/cgi/content/full/jem.20041679/DC1.
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